MX2008001506A - Uso de sales de triotropio en el tratamiento de asma severa persistente. - Google Patents

Uso de sales de triotropio en el tratamiento de asma severa persistente.

Info

Publication number
MX2008001506A
MX2008001506A MX2008001506A MX2008001506A MX2008001506A MX 2008001506 A MX2008001506 A MX 2008001506A MX 2008001506 A MX2008001506 A MX 2008001506A MX 2008001506 A MX2008001506 A MX 2008001506A MX 2008001506 A MX2008001506 A MX 2008001506A
Authority
MX
Mexico
Prior art keywords
treatment
tiotropium salts
severe
asthma
persistant asthma
Prior art date
Application number
MX2008001506A
Other languages
English (en)
Inventor
Michael Engel
Stefan Richs
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008001506(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2008001506A publication Critical patent/MX2008001506A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere al uso de sales de tiotropio para la fabricacion de un medicamento para el tratamiento de pacientes que sufren de asma severa persistente.
MX2008001506A 2005-08-06 2006-08-02 Uso de sales de triotropio en el tratamiento de asma severa persistente. MX2008001506A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107266 2005-08-06
PCT/EP2006/064958 WO2007017438A1 (en) 2005-08-06 2006-08-02 Use of tiotropium salts in the treatment of severe persistant asthma

Publications (1)

Publication Number Publication Date
MX2008001506A true MX2008001506A (es) 2008-04-07

Family

ID=35432680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001506A MX2008001506A (es) 2005-08-06 2006-08-02 Uso de sales de triotropio en el tratamiento de asma severa persistente.

Country Status (16)

Country Link
US (3) US20070032516A1 (es)
EP (1) EP1915158A1 (es)
JP (1) JP2009504604A (es)
KR (1) KR20080039974A (es)
CN (1) CN101237872A (es)
AR (1) AR055597A1 (es)
AU (1) AU2006277968A1 (es)
BR (1) BRPI0614394A2 (es)
CA (1) CA2617717C (es)
IL (1) IL189248A0 (es)
MX (1) MX2008001506A (es)
NZ (1) NZ566399A (es)
RU (1) RU2422144C2 (es)
TW (1) TWI409072B (es)
WO (1) WO2007017438A1 (es)
ZA (1) ZA200800186B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
DK1971332T3 (da) * 2006-01-04 2011-04-18 Boehringer Ingelheim Int Anvendelse af tiotropium-salte til behandling af moderat vedvarende astma
RU2012125043A (ru) * 2009-11-17 2013-12-27 Сипла Лимитед Ингаляционные растворы
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
US5888396A (en) * 1996-12-17 1999-03-30 Perriello; Felix Anthony Bioremediation of pollutants with butane-utilizing bacteria
US6156503A (en) * 1997-03-03 2000-12-05 The Regents Of The University Of California Diagnosing asthma patients predisposed to adverse β-agonist reactions
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
BR0114584A (pt) * 2000-10-12 2003-08-26 Boehringer Ingelheim Pharma Monohidrato cristalino, processos para a sua preparação e sua aplicação para a preparação de um medicamento
US6908928B2 (en) * 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
DE10216036A1 (de) * 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
WO2004014293A2 (en) * 2002-06-12 2004-02-19 Epigenesis Pharmaceuticals, Inc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
JP2005539046A (ja) * 2002-08-29 2005-12-22 シプラ・リミテッド 特異的な抗コリン作用薬、β−２アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物
US7968717B2 (en) * 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
AU2006244683A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
AU2006248189A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US20070167480A1 (en) * 2005-12-19 2007-07-19 Sicor Inc. Pure and stable tiotropium bromide
DK1971332T3 (da) 2006-01-04 2011-04-18 Boehringer Ingelheim Int Anvendelse af tiotropium-salte til behandling af moderat vedvarende astma

Also Published As

Publication number Publication date
CA2617717A1 (en) 2007-02-15
AR055597A1 (es) 2007-08-29
AU2006277968A1 (en) 2007-02-15
KR20080039974A (ko) 2008-05-07
TW200744606A (en) 2007-12-16
CN101237872A (zh) 2008-08-06
ZA200800186B (en) 2009-04-29
US20070032516A1 (en) 2007-02-08
RU2008108302A (ru) 2009-09-20
US20090163531A1 (en) 2009-06-25
RU2422144C2 (ru) 2011-06-27
IL189248A0 (en) 2008-08-07
BRPI0614394A2 (pt) 2011-03-29
WO2007017438A1 (en) 2007-02-15
CA2617717C (en) 2014-02-11
JP2009504604A (ja) 2009-02-05
TWI409072B (zh) 2013-09-21
NZ566399A (en) 2011-07-29
EP1915158A1 (en) 2008-04-30
US20130245059A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
HK1104471A1 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MX2007012538A (es) Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.
NZ596187A (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
NZ599928A (en) Use of pentosan polysulfate for treatment or prophylaxis of asthma
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
MX346186B (es) Inhibidores de proteina cinasas.
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
MY153408A (en) Novel methods
MX2008001506A (es) Uso de sales de triotropio en el tratamiento de asma severa persistente.
MX2009000991A (es) Uso de escina.
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
TW200731976A (en) Use of tiotropium salts in the treatment of moderate persistent asthma
MX2010002032A (es) Uso de flibanserina para el tratamiento de sintomas vasomotores.
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
WO2010004031A3 (en) Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
TW200833343A (en) Novel therapeutic utilization for the treatment of leukaemias
SI1714647T1 (sl) Uporaba agomelatina pri izdelavi zdravila za zdravljenje bipolarnih motenj
WO2005079769A3 (en) Piperazine derivatives for the treatment of endometriosis
MX2008011312A (es) Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos.

Legal Events

Date Code Title Description
FG Grant or registration